Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer

European Journal of Cancer ◽

10.1016/j.ejca.2019.11.022 ◽

2020 ◽

Vol 126 ◽

pp. 116-124 ◽

Cited By ~ 3

Author(s):

Florian Clatot ◽

Maxime Fontanilles ◽

Laureline Lefebvre ◽

Justine Lequesne ◽

Corinne Veyret ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Port Catheters

Download Full-text

Randomized phase II trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients

Annals of Oncology ◽

10.1093/annonc/mdz265.062 ◽

2019 ◽

Vol 30 ◽

pp. v739

Author(s):

F. Clatot ◽

M. Fontanilles ◽

L. Lefebvre ◽

J. Lequesne ◽

C. Veyret ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Cancer Patients ◽

Early Breast Cancer ◽

Phase Ii Trial ◽

Breast Cancer Patients ◽

Peripherally Inserted Central Catheters ◽

Randomized Phase Ii ◽

Central Catheters ◽

Port Catheters

Download Full-text

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4599-4 ◽

2017 ◽

Vol 168 (2) ◽

pp. 349-355 ◽

Cited By ~ 4

Author(s):

Alexios Matikas ◽

Sara Margolin ◽

Mats Hellström ◽

Hemming Johansson ◽

Nils-Olof Bengtsson ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Chemotherapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Survival Outcomes ◽

Randomized Phase Ii ◽

Dose Dense ◽

Breast Group

Download Full-text

Abstract PS1-30: A prospective phase II trial to evaluate the feasibility of omit sentinel lymph node biopsy after integrate18F-FDG dedicated axillary PET in early breast cancer: SOAPET trial

10.1158/1538-7445.sabcs20-ps1-30 ◽

2021 ◽

Author(s):

Junjie Li ◽

Jingyi Cheng ◽

Guangyu Liu ◽

Yifeng Hou ◽

Genghong Di ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Sentinel Lymph Node ◽

Sentinel Lymph Node Biopsy ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Lymph Node Biopsy ◽

Node Biopsy ◽

Prospective Phase

Download Full-text

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial

Annals of Oncology ◽

10.1093/annonc/mdy211 ◽

2018 ◽

Vol 29 (8) ◽

pp. 1777-1783 ◽

Cited By ~ 26

Author(s):

M. Ignatiadis ◽

S. Litière ◽

F. Rothe ◽

S. Riethdorf ◽

C. Proudhon ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii

Download Full-text

Abstract P1-09-05: The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)

10.1158/1538-7445.sabcs16-p1-09-05 ◽

2017 ◽

Cited By ~ 1

Author(s):

N Harbeck ◽

UA Nitz ◽

C Matthias ◽

R Kates ◽

M Braun ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

Apoptosis Markers

Download Full-text

A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer

Annals of Oncology ◽

10.1093/annonc/mdq400 ◽

2011 ◽

Vol 22 (3) ◽

pp. 609-617 ◽

Cited By ~ 10

Author(s):

A. Schneeweiss ◽

F. Marmé ◽

A. Ruiz ◽

A.G. Manikhas ◽

A. Bottini ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Neoadjuvant Treatment ◽

Randomized Phase Ii

Download Full-text

Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.573 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 573-573

Author(s):

Oleg Gluz ◽

Ulrike Nitz ◽

Cornelia Liedtke ◽

Matthias Christgen ◽

Eva-Maria Grischke ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Cancer Survival ◽

Phase Ii Trial ◽

Breast Cancer Survival

Download Full-text

The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial

Oncology ◽

10.1159/000334456 ◽

2011 ◽

Vol 81 (5-6) ◽

pp. 298-305 ◽

Cited By ~ 12

Author(s):

Tamar Safra ◽

Rinat Bernstein-Molho ◽

Julia Greenberg ◽

Sharon Pelles-Avraham ◽

Irina Stephansky ◽

...

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Bone Loss ◽

Protective Effect ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii

Download Full-text

Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.506 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 506-506 ◽

Cited By ~ 11

Author(s):

Nadia Harbeck ◽

Oleg Gluz ◽

Matthias Christgen ◽

Michael Wilhelm Braun ◽

Sherko Kummel ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Her2 Positive ◽

Hormone Receptor Positive

Download Full-text

A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps1096 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS1096-TPS1096 ◽

Cited By ~ 2

Author(s):

Peter A. Fasching ◽

Jens Uwe Blohmer ◽

Nicole Burchardi ◽

Serban Dan Costa ◽

Carsten Denkert ◽

...

Keyword(s):

Breast Cancer ◽

Homologous Recombination ◽

Neoadjuvant Chemotherapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Homologous Recombination Deficiency ◽

Randomized Phase Ii

Download Full-text